^
Association details:
| Biomarker: | EGFR G719D + EGFR L861Q + CUX1-MET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1- MET fusion
Published date:
07/26/2022
Excerpt:
...a 63-year-old woman with lung adenocarcinoma (LADC), harboring EGFR exon 18 G719D and exon 21 L861Q mutations, received first-generation...the patient was treated with osimertinib and achieved a stable disease (SD). However, disease progressed after 15 months and a novel MET fusion (CUX1 exon14-MET exon15) in addition to EGFR G719D/L861Q mutations were simultaneously detected in a tissue biopsy sample. After more than nine months, the patient subsequently achieved a PR with the combination of icotinib and crizotinib.
DOI:
10.3389/fonc.2022.911362
